Increased Collagen IV Excretion in Diabetes

Transcription

1 Pathophysiology/Complications O R I G I N A L A R T I C L E Increased Collagen IV Excretion in Diabetes A marker of compromised filtration function MARGO P. COHEN, MD GREGORY T. LAUTENSLAGER, PHD CLYDE W. SHEARMAN, PHD OBJECTIVE Increased albumin excretion in diabetes is believed to be derived from hemodynamic and/or permeability abnormalities, whereas mesangial matrix expansion gives rise to the reduction in glomerular filtration surface and decline in renal function in diabetic nephropathy. We postulated that the overproduction of extracellular matrix proteins underlying glomerulosclerosis in diabetes might be associated with the excretion of increased amounts of type IV collagen in the urine. RESEARCH DESIGN AND METHODS To explore this hypothesis, we measured the urinary excretion of (human) collagen IV by immunoassay in 65 patients with type 1 or type 2 diabetes and various degrees of albuminuria and examined its relationship to filtration function assessed by the reciprocal of the serum creatinine (RSC). RESULTS Collagen IV excretion showed a significant (P 0.001) inverse correlation (r 0.62) with the RSC, and this correlation pertained regardless of whether albumin excretion was in the low ( 100 g/mg creatinine; r 0.73) or high ( 100 g/mg; r 0.53) range. In contrast, albumin excretion showed insignificant correlation with either collagen IV excretion (r 0.12) or with the RSC (r 0.20). Urinary collagen IV was significantly higher (P 0.05) in patients with an RSC value 100 ( ng/mg creatinine) than in patients with an RSC value 100 ( ng/mg creatinine). CONCLUSIONS Because not all patients with microalbuminuria progress to declining renal function and some patients who develop nephropathy do not manifest albuminuria, the findings in this cross-sectional analysis suggest that measurement of urine collagen IV may be a useful noninvasive indicator to detect diabetic renal disease entering a phase of compromised renal function. In its earliest phases, the development of diabetic nephropathy in human patients is marked by increased urinary excretion of albumin (1). In type 1 diabetes, microalbuminuria usually does not become manifest until several years after the onset of the disease, and its appearance may antedate overt nephropathy by many years (1,2). In type 2 diabetes, microalbuminuria may be present at the Diabetes Care 24: , 2001 time of diagnosis, and the interval to appearance of overt nephropathy may be more contracted (3). As albumin excretion becomes more pronounced, glomerular structural changes are observed, most notably as an accumulation of extracellular matrix in the glomerular mesangium and a thickening of the peripheral glomerular basement membrane (4 8). As the disease progresses, loss of filtration From IMR, University City Science Center, Philadelphia, Pennsylvania. Address correspondence and reprint requests to Margo P. Cohen, MD, IMR, University City Science Center, 3508 Market St., Philadelphia, PA drmpcohen@aol.com. Received for publication 28 August 2000 and received in revised form 8 January Abbreviations: A:C, albumin:creatinine; EIA, enzyme immunosorbent assay; RSC, reciprocal of the serum creatinine; TGF, transforming growth factor. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. area and glomerular damage are reflected in a falling creatinine clearance, a rising serum creatinine, and a steady decline in renal function (6,9,10). Microalbuminuria is believed to represent leaky nephrons without overt reduction in the single nephron glomerular filtration rate, whereas a rise in serum creatinine indicates the transition from leaky to occluded glomeruli in which filtration is reduced (9). In type 1 diabetes, the magnitude of the mesangial expansion correlates positively with both the increase in albumin excretion and the reduction in the glomerular filtration rate, and there is a close inverse correlation between the degree of matrix accumulation and the glomerular surface area available for filtration (11,12). Although the structure and function changes of diabetic nephropathy are best described in type 1 diabetes, similar abnormalities are found in patients with type 2 diabetes (13,14). Although microalbuminuria is the established predictor of risk for subsequent development of diabetic nephropathy (1,15), not all patients with microalbuminuria progress to overt nephropathy, and some patients progress without antecedent microalbuminuria (16). This discrepancy is particularly notable in patients with type 2 diabetes, in whom the cumulative incidence of renal failure is usually reported to be 20%, although some populations of type 2 diabetic patients may have higher rates of end-stage renal disease (17,18), compared with a cumulative incidence of 80% in patients with type 1 diabetes who have microalbuminuria (15,19). Nosadini et al. (20) recently reported that kidney biopsy with glomerular morphometry can identify patients with type 2 diabetes in whom a decline in glomerular filtration is likely. Such patients had more thickening of the glomerular basement membrane and greater mesangial fractional volumes than patients in whom the glomerular filtration rate remained stable over a 4-year period. However, it is impractical to perform kidney biopsy on diabetic patients whose 914 DIABETES CARE, VOLUME 24, NUMBER 5, MAY 2001

2 Cohen, Lautenslager, and Shearman serum creatinine level is within the reference range, and there is currently no noninvasive way to distinguish patients who are at high risk for progression from those in whom glomerular filtration declines slowly or imperceptibly. Studies in animal models of experimental and genetic diabetes have documented that the glomerular extracellular matrix expansion responsible for the encroachment of the filtration surface area is associated with overproduction of type IV collagen (21 23). We postulated that this process might be reflected by the excretion of increased amounts of collagen IV in the urine, which could provide evidence of impending reduction in glomerular filtration surface and thereby identify patients at risk for progressive disease. We report that the urinary excretion of type IV collagen is increased in diabetic patients with albuminuria and that this increase shows a significant inverse correlation with filtration function, assessed by the reciprocal of the serum creatinine (RSC). RESEARCH DESIGN AND METHODS The study group consisted of 65 subjects (aged years) with type 1 or type 2 diabetes (American Diabetes Association criteria) who had a wide range of duration of diabetes (5 35 years) and who gave informed consent to participate in the study, which was approved by the Institutional Review Board. The mean age was lower ( years) and the mean duration of diabetes was longer in type 1 diabetic patients than in type 2 diabetic patients. All patients were currently being treated and were receiving insulin, oral hypoglycemic agents, or both. A total of 30% of the patients with type 2 diabetes and two patients with type 1 diabetes had been taking an ACE inhibitor or angiotensin receptor antagonist and had been treated with such for at least 6 months. Measurement of HbA 1c levels (highperformance liquid chromatography analysis) and fasting glucose and serum creatinine concentrations was performed in a commercial laboratory on two blood samples, obtained at a 1-month interval, and the values were averaged in each patient. Urine samples for measurement of albumin, creatinine, and type IV collagen also were obtained twice at a 1-month interval in each patient, and the values were averaged. Reciprocal of the serum creatinine was calculated from the formula 1/SCr 100, where the serum creatinine value is taken as milligrams per deciliter. Because the purpose of the study was to assess the relationship between urinary collagen IV and early decline in renal function, serum creatinine between 0.5 and 1.7 mg/dl (RSC ) was required for inclusion. Determination and definition of microalbuminuria Urine albumin was measured in random urine samples by a competitive enzymelinked immunosorbent assay in which albumin in standard or sample competes in soluble phase with human albumin immobilized onto plastic microtiter wells for binding to horseradish peroxidase conjugated antibody to human albumin (24). The assay is sensitive to 0.1 g and shows linearity with the log of concentration between 10 and 1,000 g/ml. Intraassay and interassay coefficients of variation are 3 and 4 6%, respectively. Creatinine was measured in the same sample by a colorimetric method (Sigma, St. Louis, MO) to calculate the urine albumin:creatinine (A:C) ratio. This ratio is regarded as one of the best accepted means for assessing urinary albumin excretion and is recommended by the American Diabetes Association (3) and by Warram and colleagues (25 28), who have used it to establish sex-specific ranges delineating normoalbuminuria, microalbuminuria, and overt proteinuria and levels of microalbuminuria associated with declining glomerular filtration function (25). Warram s definition of microalbuminuria provides a lower limit of 17 g/mg for men and a lower limit of 25 g/mg for women (25,28). Collagen IV immunoassay The immunoassay for quantitation of type IV collagen used type IV collagen purified from human placenta (Collaborative Biomedical Products, Bedford, MA) and rabbit anti-human type IV collagen antibody (Biodesign, Kennebunk, ME), according to previously described methodology (29). The antigen was coated onto plastic microtiter wells (125 ng/well) in carbonate-bicarbonate coupling buffer (ph 9.6), and the wells were blocked with 0.1% bovine serum albumin in glycine coupling buffer, ph 8.5, containing 0.05% Proclin (Supelco, Bellefonte, PA). To initiate the assay, plates were washed with enzyme immunosorbent assay (EIA) buffer (0.15 mol/l NaCl, 10 mmol/l triethanolamine, ph 6.8, containing 0.01% Tween-20) and blotted by inversion. A total of 200 lofa solution containing standard or sample and anti-human collagen IV antibody in 10% fetal calf serum, 100 mmol/l Tris HCl, ph 7.5, was added to the wells and allowed to react for 1 h at room temperature. This solution was prepared by adding equal volumes of standard or sample, diluted in EIA buffer, and the primary antibody (1:2,000 dilution in the same buffer) to microfuge tubes and preincubating overnight at room temperature. The preincubation step enhances binding of antibody to antigen in the soluble phase, reducing binding to coated antigen when competing antigen is present in low concentrations and allowing measurement in unconcentrated specimens. Horseradish peroxidase conjugated goat anti-rabbit IgG (1:2,000 dilution in 10% bovine serum albumin, 100 mmol/l Tris HCl) was then added to the wells, and the incubation was continued for another hour. The plates were washed and developed with TMBlue substrate, stopped, and read as described above. The assay was sensitive to 5 ng/ml and showed a linear inverse relationship with the log of concentration between 5 and 2,000 ng/ml. Intra-assay and interassay coefficients of variation were 9%, and the average intraindividual variation between the two specimens was 13%. The anti-collagen IV antibody showed no reactivity with other human urinary proteins (the principal one being albumin). Glucose up to 50 mmol/l did not interfere in the assay. None of the subjects had ketonuria or evidence of urinary tract infection. Statistical analysis Statistical analysis was performed using unpaired t tests to compare means. Correlations between analyses were determined by linear regression analysis. RESULTS The clinical characteristics of the study population are summarized in Table 1. As a group, the patients had suboptimal control of diabetes with a mean fasting glucose concentration of mmol/l (range ) and a mean HbA 1c of 8.9% (range ). The mean HbA 1c was significantly higher in patients with type 1 diabetes than in those with type 2 diabetes ( and %, respectively). Serum DIABETES CARE, VOLUME 24, NUMBER 5, MAY

3 Urinary collagen IV in diabetes Table 1 Clinical characteristics of the study population n 65 Type 1 diabetes 18 Type 2 diabetes 47 Age (years) (range 27 74) Sex (male/female) 50/15 Duration of diabetes (years) (range 5 35) BMI (range ) Type 1 diabetes Type 2 diabetes Fasting glucose (mmol/l) (range ) HbA 1c (%) (range ) Urine A:C ratio ( g/mg) * (range 5.7 3,080) Serum creatinine ( mol/l) (range ) Data are means SEM unless otherwise indicated. *Median 102.5; log values of ; , excluding the outlier. creatinine concentrations were 1.7 mg/dl ( 150 mol/l) in all patients, and the mean SEM value for the RSC was The mean urine albumin excretion was 216 g/mg creatinine, a value falling clearly within the microalbuminuric range. Four patients had values 20 g/mg, and 10 patients had values in the overt proteinuric range ( 350 g/mg). The mean A:C ratio was in patients with type 1 diabetes and in patients with type 2 diabetes, and the median A:C ratios were 79.2 and 93.6, respectively. Urine excretion of collagen IV ranged from 6.8 to 52.8 ng/mg creatinine (mean 20.9 ng/mg). The mean value for urine collagen IV in 12 volunteers with albumin excretion 10 g/mg creatinine was 6.6 ng/mg creatinine (range ; intraindividual variability 9%). Collagen IV excretion showed no significant correlation with albumin excretion (r 0.12 with analysis of 64 of 65 patients, excluding an outlier with A:C ratio of 3,080) but had a significant inverse correlation (r 0.62) with RSC values (Fig. 1). In the 65 patients studied, urine collagen IV did not correlate with HbA 1c levels (r 0.03). Considering the data of Warram et al. (25), which suggest that a decline in RSC begins to be detectable when A:C ratios exceed 100 g/mg, the patients in this Figure 1 Correlation analysis in study population of urinary type IV collagen (ng/mg creatinine) with A:C ratios (A: r 0.12; NS when outlier at A:C ratio of 3,080 is excluded; r 0.37, P 0.10 when outlier is included) and with RSC values (B: r 0.62; P 0.001). study were divided into two groups according to albumin excretion. The mean SEM RSC in subjects with an A:C ratio 100 g/mg was and in patients with an A:C ratio 100 (P 0.05). Urine collagen IV showed a significant inverse correlation with RSC values in patients with either low (r 0.73) or high (r 0.53) albumin excretion (Fig. 2). In contrast, there was no significant correlation between A:C ratios and RSC values, whether analyzed as all patients (Fig. 3) or separated into patients with low versus high albumin excretion. Using the approach of Warram et al. (28), who segmented microalbuminuric patients into four groups according to HbA 1c levels in assessing risk for progressive disease, we evaluated albumin excretion and RSC values in our study population similarly divided into groups according to HbA 1c. The mean A:C ratio was lower in patients with HbA 1c between 5.1 and 5.9% (128 27; n 21) and between 9.0 and 9.9% (98 21; n 10) than in patients in the other two categories of HbA 1c values ( , n 17, HbA 1c %; and , n 17; HbA 1c %). However, the mean RSC value in patients with HbA 1c 10% was significantly higher at (P 0.05) than in patients with HbA 1c levels in the other three categories (108 4, 104 3, and 109 8), suggesting that hyperfiltration in conjunction with poor Figure 2 Correlation analysis of urinary type IV collagen (ng/mg creatinine) with RSC values in patients with A:C ratios 100 g/mg (A: r 0.73) or 100 g/mg (B: r 0.53). The mean SEM A:C ratios in these two groups were and , respectively, and the respective median values were 55.7 and DIABETES CARE, VOLUME 24, NUMBER 5, MAY 2001

4 Cohen, Lautenslager, and Shearman Figure 3 Correlation analysis in study population of urinary A:C ratios with RSC values (r 0.20, NS, in 65 subjects; r 0.19, NS, excluding the outlier with A:C ratio of 3,080). glucose control contributed to increased albumin excretion in this group. Nine of the patients in this HbA 1c category had type 1 diabetes. To further explore the relationship between RSC as a measure of declining filtration function and urinary collagen IV as a marker of glomerular matrix expansion compromising the filtration surface area, subjects were divided into two groups: RSC 100 (corresponding to a serum creatinine 1.0 mg/dl or 88 mol/l) and RSC 100 (corresponding to a serum creatinine 1.0 mg/dl or 88 mol/l). This value was arbitrarily selected from results in published studies, indicating that decline in filtration function with time can begin to be detected at this level (25,30,31). HbA 1c values were and , respectively, in these two groups. Three patients with type 1 diabetes and 23 patients with type 2 diabetes had RSC values 100. Urinary collagen IV excretion was significantly higher ( ng/mg creatinine) in patients with RSC 100 than in patients with RSC 100 ( ng/mg creatinine). The mean SEM urine albumin excretion in patients with RSC 100 was (n 39) and was (n 26) in patients with RSC 100. CONCLUSIONS The principal findings in this study are that the excretion of type IV collagen is increased in diabetic patients with albuminuria and that urinary collagen IV levels in these patients correlate inversely with the RSC. These results suggest that an increase in collagen IV excretion accompanies the overproduction of this extracellular matrix protein in the course of the development of diabetic nephropathy. As expansion of the glomerular extracellular matrix encroaches on the glomerular filtration surface area, filtration function begins to decline, as evidenced by decreasing RSC. The increased collagen IV excretion may reflect the clinical onset of this process. Long-term studies are needed to confirm whether overt nephropathy is more likely to develop in albuminuric patients with elevated versus normal urinary collagen IV excretion. Other investigators have reported that the excretion of the fibrogenic cytokine transforming growth factor (TGF)- 1, which has been pathogenetically implicated in diabetic nephropathy, and of collagen IV as markers of renal fibrogenesis is elevated in microalbuminuric diabetic patients (32). Increased renal production of TGF- 1 in human diabetes, evidenced by overexpression of the cytokine and by TGF- 1 concentrations in renal vein effluent, also has been described (33,34). The relatively modest increase in TGF- 1 excretion that was observed in patients with microalbuminuria or with overt proteinuria did not correlate with the much larger (sixfold) increase in collagen excretion in these patients (32), suggesting that factors other than TGF- 1 are important in the enhanced matrix production and/or that altered renal handling of matrix proteins may be responsible for the elevated collagen excretion. However, collagen IV excretion has been shown to be elevated in the diabetic db/db mouse, a rodent model of genetic diabetes that develops glomerular pathology similar to that which occurs in human diabetes (35). Notably, the increase in collagen IV excretion in db/db mice postdated the development of albuminuria, which becomes manifest soon after the onset of hyperglycemia, and coincided with histopathological evidence of glomerular matrix accumulation and the onset of a decreasing creatinine clearance. These findings are consistent with the interpretation that collagen IV excretion is a marker of glomerular basement membrane synthesis and matrix remodeling. Although the data of Warram et al. (25) suggest that decline in RSC correlates with increasing albuminuria at an A:C ratio 100, we did not find a significant negative correlation between A:C ratios and RSC values in patients with either higher (A:C 100) or lower (A:C 100) levels of albumin excretion. However, urinary collagen IV showed a significant inverse relationship with the RSC in patients in whom the A:C ratio was either 100 or 100. The significant correlation of collagen IV excretion with RSC values in patients with A:C ratios 100 g/mg is of special interest because it suggests that, in patients with lower levels of microalbuminuria and especially in type 2 diabetic patients (who represented 70% of our study population), urinary collagen IV excretion may be a better indicator than the A:C ratio of impending decline in filtration function. The findings in this cross-sectional study support the hypothesis that elevated collagen IV excretion is an indicator of diabetic renal disease entering a phase of compromised filtration function. Longitudinal studies in which filtration function is carefully monitored in patients with type 1 and type 2 diabetes are needed for confirmation. DIABETES CARE, VOLUME 24, NUMBER 5, MAY

5 Urinary collagen IV in diabetes Acknowledgments This study was supported in part by National Institutes of Health Grants DK and DK We thank Mr. Hai Pham for technical assistance. References 1. Mogensen CE, Christiansen CK, Vittinghus E: The stages of diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Suppl. 2):64 78, Viberti G, Keen H: The patterns of proteinuria in diabetes mellitus: relevance to pathogenesis and prevention of diabetic nephropathy. Diabetes 33: , American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care 23 (Suppl. 1):69 72, Steffes MW, Bilous RW, Sutherland DER, Brown DM, Goetz F: Structure function relationships in diabetic nephropathy. J Clin Invest 4: , Fioretto P, Steffes MW, Mauer M: Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43: , Ellis EN, Steffes MW, Goetz FC, Sutherland DER, Mauer SM: Glomerular filtration surface in type I diabetes mellitus. Kidney Int 29: , Osterby R, Parving HH, Hommel E, Jorgensen JE, Lokkegard H: Glomerular structure and function in diabetic nephropathy: early to advanced stages. Diabetes 39: , Steffes MW, Bilous RW, Sutherland DER, Mauer SM: Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 41: , Sawicki PT, Berger M: Measuring progression of diabetic nephropathy. Eur J Clin Invest 24: , Schmitz A, Gunderson HJG, Osterby R: Glomerular morphology by light microscopy in non-insulin dependent diabetes mellitus: lack of glomerular hypertrophy. Diabetes 37:38 43, Lane PH, Steffes MW, Fioretto P, Mauer SM: Renal interstitial expansion in insulin-dependent diabetes mellitus in the kidney. Kidney Int 43: , Bohle A, Wehrmann M, Bogenschultz O, Batz C, Muller GA: The pathogenesis of chronic renal failure in diabetic nephropathy. Pathol Res Pract 187: , Ueno M, Kawashima S, Nihsi S, Shimada S, Shimada N, Karasawa R, Suzuki Y, Muruyama Y, Arakawa M: Tubulointerstitial lesions in non-insulin dependent diabetes mellitus. Kidney Int 52:S191 S194, White KE, Bilous RW: Type 2 diabetic patients with nephropathy show structuralfunctional relationships that are similar to type 1 disease. J Am Soc Nephrol 11: , Mogensen CE: Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31: , Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, Jerums G: Progressive decline in renal function in diabetic patients with and without microalbuminuria. Diabetes 43: , Hasslacher C, Ritz E, Wahl P, Michael C: Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 4: , Kunzelman CL, Knowler W, Pettitt DJ, Bennett PH: Incidence of nephropathy in type 2 diabetes mellitus in the Pima Indians. Kidney Int 35: , Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O Fallon M, Palumbo PJ: Chronic renal failure in non-insulin dependent diabetes mellitus: a population based study in Rochester, Minnesota. Ann Intern Med 11: , Nosadini R, Velussi M, Brocco E, Brueghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato E, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli E, Sfriso A, Fioretto P: Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 49: , Abrass CK, Peterson CV, Raugi GS: Phenotypic expression of collagen types in mesangial matrix of diabetic and nondiabetic rats. Diabetes 37: , Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. J Clin Invest 95: , Ziyadeh FN, Hoffman BB, Han DC, Iglesias-d-la-Cruz M, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Longterm prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor- antibody in db/db diabetic mice. Proc Natl Acad Sci USA97: , Neuman RG, Cohen MP: Improved competitive enzyme linked immunoassay (ELISA) for albuminuria. Clin Chim Acta 179: , Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type 1 diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/ creatinine ratio. J Am Soc Nephrol 7: , Warram JH, Krolewski AS: Use of the albumin/creatinine ratio in patient care and clinical studies. In The Kidney and Hypertension in Diabetes Mellitus. Mogensen CE, Ed. Boston, MA, Kluwer Academic, 1998, p Krolewski AS, Laffel L, Krolewski M, Quinn M, Warram JH: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332: , Warram JH, Scott LJ, Hanna LS, Wantman M, Cohen SE, Laffel LMB, Ryan L, Krolewski AS: Progression of microalbuminuria to proteinuria in type 1 diabetes. Diabetes 49:94 100, Cohen MP, Ziyadeh FN: Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int 45: , Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: , Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus. Arch Intern Med 156: , Ellis D, Forrest KY-Z, Erbey J, Orchard TJ: Urinary measurement of transforming growth factor and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 44: , Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BRC: Increased renal production of transforming growth factor- 1 in patients with type II diabetes. Diabetes 46: , Yamamoto T, Nakamura T, Nobel N, Rouslahti E, Border WA: Expression of transforming growth factor is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90: , Cohen MP, Lautenslager GT, Shearman CW: Increased urinary collagen IV in diabetic nephropathy (Abstract). Diabetes 49:A153, DIABETES CARE, VOLUME 24, NUMBER 5, MAY 2001